Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, Magainin deal

The companies will co-develop an anti-IL-9 antibody to treat asthma, with options to include other respiratory disease

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE